Efficacy and Safety of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion Administered as Monotherapy in Patients with Parkinson's Disease

被引：0
|
作者：
Aldred, J.
Henriksen, T.
Bouchard, M.
Martinez-Castrillo, J.
Soileau, M.
Spiegel, A.
Bergmann, L.
Gupta, R.
Kukreja, P.
Standaert, D.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
19
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [31] Neutrophil-Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa
    Weise, David
    Haferkamp, Sebastian
    MOVEMENT DISORDERS, 2025, 40 (02) : 389 - 390
  • [32] Challenges with Oral Anti-Parkinsonian Medications and Opportunities with Continuous Subcutaneous Infusion (CSCI) Of Foslevodopa/Foscarbidopa (LDP/CDP) for Treatment of Advanced Parkinson's Disease (aPD)
    Aldred, J.
    Soileau, M.
    Yan, C.
    Brion, T.
    Bellenger, A.
    Suh, J.
    O'Donnell, C.
    Kukreja, P.
    Facheris, M.
    Shewale, A.
    Kumar, R.
    MOVEMENT DISORDERS, 2023, 38 : S8 - S9
  • [33] Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson's disease (PD)
    Hauser, R.
    Bouchard, M.
    Santos-Garcia, D.
    Bergmann, L.
    Gupta, R.
    Harmer, L.
    Shah, M.
    Yan, C.
    Isaacson, S.
    MOVEMENT DISORDERS, 2024, 39 : S340 - S341
  • [34] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial (vol 21, pg 1099, 2022)
    Soileau, M. J.
    Aldread, J.
    Budur, K.
    LANCET NEUROLOGY, 2023, 22 (03): : E5 - E5
  • [35] Reply to: "Neutrophil-Rich Infusion Site Reactions after Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa"
    Yoshihara, Nagisa
    Watanabe, Rei
    Nishikawa, Noriko
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2025, 40 (02) : 391 - 392
  • [36] Continuous subcutaneous apomorphine monotherapy in Parkinson's disease
    Papuc, Ewa
    Trzciniecka, Olga
    Rejdak, Konrad
    ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE, 2019, 26 (01) : 133 - 137
  • [37] Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease
    Huters, Alexander D.
    Stambuli, James
    Klix, Russell C.
    Matulenko, Mark A.
    Chan, Vincent S.
    Simanis, Justin
    Hill, David R.
    Reddy, Rajarathnam E.
    Towne, Timothy B.
    Bellettini, John R.
    Kotecki, Brian J.
    Cardinal-David, Benoit
    Ji, Jianguo
    Voight, Eric A.
    Shou, Minshan
    Balaraman, Selvakumar
    Ashok, Abhishek
    Ghosh, Soma
    JOURNAL OF ORGANIC CHEMISTRY, 2022, 87 (04): : 1986 - 1995
  • [38] Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa-Foscarbidopa Hydrate: Histopathology
    Yoshihara, Nagisa
    Nishikawa, Noriko
    Watanabe, Rei
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2025, 40 (02) : 378 - 379
  • [39] Foslevodopa/Foscarbidopa in Patients with Advanced Parkinson's Disease: Subgroup Analyses from a Phase 3, Randomized Study
    Soileau, M.
    Fisseha, N.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Robieson, W.
    Talapala, S.
    Vaou, E.
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2023, 38 : S51 - S51
  • [40] Treatment Patterns with Long-Term Foslevodopa/Foscarbidopa Use in Parkinson's disease (PD)
    Aldred, J.
    Henriksen, T.
    Bouchard, M.
    Martinez-Castrillo, J.
    Soileau, M.
    Standaert, D.
    Bergmann, L.
    Gupta, R.
    Kukreja, P.
    Shah, M.
    Isaacson, S.
    MOVEMENT DISORDERS, 2024, 39 : S325 - S326
12345